iPSC_F199001_C3_CRISPR_CACNA1C_T330M_HTZ_C11.2
The cell line is not validated yet.
BBANTWi012-A-6
General
Cell Line |
|
| hPSCreg name | BBANTWi012-A-6 |
| Cite as: | BBANTWi012-A-6 |
| Alternative name(s) |
iPSC_F199001_C3_CRISPR_CACNA1C_T330M_HTZ_C11.2
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines | No similar lines found. |
| Last update | 2nd October 2025 |
| User feedback | |
Provider |
|
| Generator | Biobank Antwerpen (BBANTW) |
External Databases |
|
| BioSamples | SAMEA120297612 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
| Subclone of | |
Donor Information
General Donor Information |
|
| Sex | female |
| Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA115545255 |
Ethics
Also have a look at the ethics information for the parental line
BBANTWi012-A
.
| Is there an MTA available for the cell line? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
BBANTWi012-A.
|
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Is reprogramming vector detectable? |
No |
| Methods used |
PCR
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| O2 Concentration | 5 % |
| CO2 Concentration | 5 % |
| Medium |
Essential 8™ Flex
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| SOX2 |
Yes |
|||||
| TRA 1-60 |
Yes |
|||||
| POU5F1 (OCT-4) |
Yes |
|||||
| TRA 1-81 |
Yes |
|||||
| NANOG |
Yes |
Morphology pictures
Differentiation Potency
In vitro directed differentiation
| Marker | Expressed |
| SOX17 |
Yes |
| FOXA2 |
Yes |
| CXCR4 |
Yes |
Morphology
In vitro directed differentiation
| Marker | Expressed |
| NKX2-5 |
Yes |
| HAND1 |
Yes |
Morphology
In vitro directed differentiation
| Marker | Expressed |
| HES5 |
Yes |
| MAP2 |
Yes |
| PAX6 |
Yes |
Morphology
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46,XX. No clinically significant abnormalities observed.
Karyotyping method:
Molecular karyotyping by SNP array
http:// |
Other Genotyping (Cell Line) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
SNP typing array
Genotyped with Illumina's HumanCytoSNP-12 v2.1. No clinically significant CNVs observed after CRISPR editing relative to the donor line |
Genetic Modification
| Disease/phenotype related modifications |
|
| Genetic modifications not related to a disease |
|
Login to share your feedback, experiences or results with the research community.